0
New sequencing studies shed more light on the B.1.1.7 SARS-CoV-2 variant
Two new studies have shed light on the B.1.1.7 variant, suggesting that while it is more transmissible, it does not…
Browsing: Research > Basic
0
nAbbing SARS-CoV-2 variants
New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them. With the COVID-19 pandemic on its third wave in some…
0
What effect will SARS-CoV-2 variants have on vaccine efficacy?
The ‘inevitable’ domination of novel SARS-CoV-2 variants from Brazil, South Africa and the UK could result in less effective COVID-19…
0
One drug to rule them all?
Thapsigargin, a promising broad-spectrum antiviral, has proven effective for use against SARS-CoV-2, as well as the influenza A and respiratory…
0
Natural immunity to COVID-19: how long and how strong?
Two recent papers from Public Health England (PHE; London, UK) and Rockefeller University (NY, USA) have shed new light on the duration and quality of protection provided…
0
A nasal spray a day could keep COVID-19 away
Hands, face, space. These are the three tools available to everyday citizens to prevent the spread of COVID-19; the simple…
0
Everything we know about the UK’s novel, emergent strain of COVID-19
As a new COVID-19 strain emerges in the southeast of England that appears to be more infectious than previous strains, what do…
0
How has COVID-19 impacted research?
Discover the vast impacts of the COVID-19 pandemic on the lab research community: from funding cuts, to PhD students changing…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…